Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) saw a large decline in short interest in August. As of August 15th, there was short interest totalling 33,400 shares, a decline of 20.1% from the July 31st total of 41,800 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 33,400 shares, the short-interest ratio is presently 1.0 days.
Virpax Pharmaceuticals Stock Performance
VRPX opened at $0.90 on Wednesday. The stock’s fifty day moving average is $0.94 and its 200-day moving average is $0.88. The company has a market capitalization of $10.54 million, a PE ratio of -0.69 and a beta of 2.10. Virpax Pharmaceuticals has a one year low of $0.61 and a one year high of $1.39.
Institutional Inflows and Outflows
Virpax Pharmaceuticals Company Profile
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
- Five stocks we like better than Virpax Pharmaceuticals
- How to Invest in the FAANG Stocks
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- Consumer Staples Stocks, Explained
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- Best Stocks Under $10.00
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.